Primary Care Is Starving While Training Hospitals Feast
-
By
-
Kerri Miller
-
May 11, 2026
-
2 min
By
Kerri Miller
May 11, 2026
ASE 2026 data support further development of MVT-100 in pivotal trials.
June 27, 2026
Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.
June 29, 2026
A meta-analysis of placebo-controlled crossover trials found reduced aerobic time-trial completion times with both low- and moderate-dose oral anhydrous caffeine, but the evidence was mostly derived from male participants, cycling studies, and trials using doses no higher than 6 mg/kg.
June 29, 2026